Magdalena Kotańska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4285066/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The influence of the route of administration of gold nanoparticles on their tissue distribution and basic biochemical parameters: In vivo studies. Pharmacological Reports, 2015, 67, 405-409.	1.5	77
2	The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT6 Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment. International Journal of Molecular Sciences, 2019, 20, 3420.	1.8	43
3	Alpha lipoic acid protects the heart against myocardial post ischemia–reperfusion arrhythmias via KATP channel activation in isolated rat hearts. Pharmacological Reports, 2014, 66, 499-504.	1.5	38
4	Antinociceptive, anti-inflammatory and smooth muscle relaxant activities of the pyrrolo[3,4-d]pyridazinone derivatives: Possible mechanisms of action. Pharmacology Biochemistry and Behavior, 2015, 133, 99-110.	1.3	35
5	Idalopirdine – a small molecule antagonist of 5-HT6 with therapeutic potential against obesity. Metabolic Brain Disease, 2015, 30, 1487-1494.	1.4	35
6	Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating. Metabolic Brain Disease, 2018, 33, 733-740.	1.4	30
7	A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity. PLoS ONE, 2015, 10, e0141327.	1.1	28
8	The role of lipoic acid in prevention of nitroglycerin tolerance. European Journal of Pharmacology, 2008, 591, 203-210.	1.7	27
9	Effects of Different Garlicâ€derived Allyl Sulfides on Peroxidative Processes and Anaerobic Sulfur Metabolism in Mouse Liver. Phytotherapy Research, 2012, 26, 425-431.	2.8	26
10	H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice. Metabolic Brain Disease, 2016, 31, 1023-1029.	1.4	24
11	Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H3R ligands. European Journal of Medicinal Chemistry, 2018, 152, 223-234.	2.6	24
12	PSB 603 – a known selective adenosine A2B receptor antagonist – has anti-inflammatory activity in mice. Biomedicine and Pharmacotherapy, 2021, 135, 111164.	2.5	21
13	Are anti-inflammatory properties of lipoic acid associated with the formation of hydrogen sulfide?. Pharmacological Reports, 2013, 65, 1018-1024.	1.5	20
14	Single Administration of HBK-15—a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist—Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. Molecular Neurobiology, 2018, 55, 3931-3945.	1.9	20
15	Novel and effective synthesis protocol of AgNPs functionalized using L-cysteine as a potential drug carrier. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 123-130.	1.4	19
16	Tissue distribution of gold nanoparticles after single intravenous administration in mice. Pharmacological Reports, 2013, 65, 1033-1038.	1.5	18
17	HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. Behavioural Brain Research, 2017, 333, 54-66.	1.2	18
18	Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT6 Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo. Molecules, 2018, 23, 2529.	1.7	18

Magdalena Kotańska

#	Article	IF	CITATIONS
19	The histamine H3 receptor inverse agonist pitolisant reduces body weight in obese mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 875-881.	1.4	18
20	Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro. Molecules, 2019, 24, 4472.	1.7	18
21	Chemically Homogenous Compounds with Antagonistic Properties at All α1-Adrenoceptor Subtypes but not β1-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in Rats. Frontiers in Pharmacology, 2016, 7, 229.	1.6	17
22	Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenylpiperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action. Pharmacology Biochemistry and Behavior, 2016, 141, 28-41.	1.3	17
23	Metabolic and Cardiovascular Benefits and Risks of EMD386088—A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor. Frontiers in Neuroscience, 2017, 11, 50.	1.4	16
24	Antiâ€Alzheimer's multitargetâ€directed ligands with serotonin 5â€HT ₆ antagonist, butyrylcholinesterase inhibitory, and antioxidant activity. Archiv Der Pharmazie, 2019, 352, e1900041.	2.1	16
25	Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity. European Journal of Pharmacology, 2016, 776, 146-155.	1.7	15
26	KSK19 – Novel histamine H3 receptor ligand reduces body weight in diet induced obese mice. Biochemical Pharmacology, 2019, 168, 193-203.	2.0	15
27	In Vivo Anti-inflammatory Activity of Lipoic Acid Derivatives in Mice. Postepy Higieny I Medycyny Doswiadczalnej, 2013, 67, 331-338.	0.1	15
28	Structural modifications and in vitro pharmacological evaluation of 4-pyridyl-piperazine derivatives as an active and selective histamine H3 receptor ligands. Bioorganic Chemistry, 2019, 91, 103071.	2.0	14
29	Synthesis and biological evaluation of <i>N</i> -arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2 <i>H</i> ,4 <i>H</i>)-dione as potential antiplatelet agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 536-545.	2.5	13
30	Optimization and preclinical evaluation of novel histamine H3receptor ligands: Acetyl and propionyl phenoxyalkyl piperazine derivatives. Bioorganic and Medicinal Chemistry, 2018, 26, 6056-6066.	1.4	12
31	α-Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-one. Bioorganic and Medicinal Chemistry, 2015, 23, 2104-2111.	1.4	11
32	Reversal of cardiac, vascular, and renal dysfunction by non-quinazoline α1-adrenolytics in DOCA-salt hypertensive rats: a comparison with prazosin, a quinazoline-based α1-adrenoceptor antagonist. Hypertension Research, 2019, 42, 1125-1141.	1.5	11
33	Evaluation of antidepressant-like and anxiolytic-like activity of purinedione-derivatives with affinity for adenosine A2A receptors in mice. Pharmacological Reports, 2016, 68, 1285-1292.	1.5	10
34	KD-64—A new selective A2A adenosine receptor antagonist has anti-inflammatory activity but contrary to the non-selective antagonist—Caffeine does not reduce diet-induced obesity in mice. PLoS ONE, 2020, 15, e0229806.	1.1	10
35	Structural modifications in the distal, regulatory region of histamine H3 receptor antagonists leading to the identification of a potent anti-obesity agent. European Journal of Medicinal Chemistry, 2021, 213, 113041.	2.6	10
36	Evaluation of anticonvulsant activity of novel pyrrolidin-2-one derivatives. Pharmacological Reports, 2014, 66, 708-711.	1.5	9

Magdalena Kotańska

#	Article	IF	CITATIONS
37	Antiarrhythmic activity of new 2-methoxyphenylpiperazine xanthone derivatives after ischemia/reperfusion in rats. Pharmacological Reports, 2015, 67, 1163-1167.	1.5	9
38	Hypotensive effect of alpha-lipoic acid after a single administration in rats. Anatolian Journal of Cardiology, 2015, 16, 306-9.	0.5	9
39	Anti-aggregation effect of aroxyalkyl derivatives of 2-methoxyphenylpiperazine is due to their 5-HT2A and α2-adrenoceptor antagonistic properties. A comparison with ketanserin, sarpogrelate, prazosin, yohimbine and ARC239. European Journal of Pharmacology, 2018, 818, 263-270.	1.7	8
40	Beneficial effects of non-quinazoline α1-adrenolytics on hypertension and altered metabolism in fructose-fed rats. AÂcomparison with prazosin. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 751-760.	1.1	8
41	Antinociceptive, antiedematous, and antiallodynic activity of 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives in experimental models of pain. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 813-827.	1.4	8
42	Design, Sustainable Synthesis and Biological Evaluation of a Novel Dual α2A/5-HT7 Receptor Antagonist with Antidepressant-Like Properties. Molecules, 2021, 26, 3828.	1.7	8
43	HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in Rats. PLoS ONE, 2016, 11, e0165495.	1.1	8
44	Involvement of the NO/sGC/cGMP/K+ channels pathway in vascular relaxation evoked by two non-quinazoline α1-adrenoceptor antagonists. Biomedicine and Pharmacotherapy, 2018, 103, 157-166.	2.5	7
45	Metabolic benefits of 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one: a non-selective α-adrenoceptor antagonist. Journal of Endocrinological Investigation, 2018, 41, 609-619.	1.8	7
46	Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT1A receptor partial agonists. PLoS ONE, 2020, 15, e0237196.	1.1	7
47	Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating. Pharmaceuticals, 2021, 14, 270.	1.7	7
48	The GPR18 Agonist PSB-KD-107 Exerts Endothelium-Dependent Vasorelaxant Effects. Pharmaceuticals, 2021, 14, 799.	1.7	7
49	Synthesis and Pharmacological Activity of a New Series of 1â€(1 <i>H</i> â€Indolâ€4â€yloxy)â€3â€(2â€(2â€methoxyphenoxy)ethylamino)propanâ€2â€ol Analogs. Archiv 2016, 349, 211-223.	Der2Pharm	nazi@,
50	MH-76, a Novel Non-Quinazoline α1-Adrenoceptor Antagonist, but Not Prazosin Reduces Inflammation and Improves Insulin Signaling in Adipose Tissue of Fructose-Fed Rats. Pharmaceuticals, 2021, 14, 477.	1.7	6
51	Metabolic benefits of novel histamine H3 receptor ligands in the model of excessive eating: The importance of intrinsic activity and pharmacokinetic properties. Biomedicine and Pharmacotherapy, 2021, 142, 111952.	2.5	6
52	The effect of nitroglycerin tolerance on oxidative stress and anaerobic sulfur metabolism in rat tissues. Fundamental and Clinical Pharmacology, 2010, 24, 47-53.	1.0	5
53	Pitolisant protects mice chronically treated with corticosterone from some behavioral but not metabolic changes in corticosterone-induced depression model. Pharmacology Biochemistry and Behavior, 2020, 196, 172974.	1.3	5
54	Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia. Journal of Medicinal Chemistry, 2021, 64, 12603-12629.	2.9	5

#	Article	IF	CITATIONS
55	Hydroalcoholic Leaf Extract of Isatis tinctoria L. via Antioxidative and Anti-Inflammatory Effects Reduces Stress-Induced Behavioral and Cellular Disorders in Mice. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-18.	1.9	5
56	Can Lipoic Acid Attenuate Cardiovascular Disturbances Induced by Ethanol and Disulfiram Administration Separately or Jointly in Rats?. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-10.	1.9	4
57	Antiarrhythmic and αâ€Adrenoceptor Antagonistic Properties of Novel Arylpiperazine Derivatives of Pyrrolidinâ€2â€one. Archiv Der Pharmazie, 2015, 348, 861-867.	2.1	3
58	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as $\hat{I} \pm 1$ -adrenergic receptor antagonist with uro-selective activity. Bioorganic and Medicinal Chemistry, 2016, 24, 5582-5591.	1.4	3
59	Discovery of Potential, Dual-Active Histamine H3 Receptor Ligands with Combined Antioxidant Properties. Molecules, 2021, 26, 2300.	1.7	3
60	Influence of betahistine repeated administration on a weight gain and selected metabolic parameters in the model of excessive eating in rats. Biomedicine and Pharmacotherapy, 2021, 141, 111892.	2.5	3
61	Histamine H3 Receptor Ligands—KSK-59 and KSK-73—Reduce Body Weight Gain in a Rat Model of Excessive Eating. Pharmaceuticals, 2021, 14, 1080.	1.7	3
62	Is the mechanism of nitroglycerin tolerance associated with aldehyde dehydrogenase activity? A contribution to the ongoing discussion. Acta Biochimica Polonica, 2019, 66, 627-632.	0.3	3
63	KSK-74: Dual Histamine H3 and Sigma-2 Receptor Ligand with Anti-Obesity Potential. International Journal of Molecular Sciences, 2022, 23, 7011.	1.8	3
64	Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug l-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats. Pharmacological Reports, 2017, 69, 29-35.	1.5	2
65	Synthesis and Pharmacological Evaluation of Novel Silodosin-Based Arylsulfonamide Derivatives as α1A∫α1D-Adrenergic Receptor Antagonist with Potential Uroselective Profile. Molecules, 2018, 23, 2175.	1.7	2
66	Yohimbine improves lipid and carbohydrate profiles without reduction in body weight in obese leptin-deficient ob/ob mice. Journal of Pre-Clinical and Clinical Research, 2018, 12, 67-71.	0.2	2
67	Guanabenz—an old drug with a potential to decrease obesity. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 963-974.	1.4	2
68	The effect of NaCl on the level of reduced sulfur compounds in rat liver. Implications for blood pressure increase. Postepy Higieny I Medycyny Doswiadczalnej, 2017, 71, 0-0.	0.1	1
69	Antiarrhythmic activity in occlusionâ€reperfusion model of 1â€{1Hâ€indolâ€4â€yloxy)â€3â€{[2â€{2â€methoxyphenoxy)ethyl]amino} propanâ€2â€ol and its enantiomers Experimental Pharmacology and Physiology, 2016, 43, 81-87.	s. Climizal ai	nd o
70	Title is missing!. , 2020, 15, e0229806.		0
71	Title is missing!. , 2020, 15, e0229806.		0

#	Article	IF	CITATIONS
73	Title is missing!. , 2020, 15, e0229806.		0